Dataset Information


Randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration.

ABSTRACT: This prospective multicenter randomized comparative cross-over trial aimed at evaluating the influence of hemodialysis vs post-dilution hemodiafiltration with high-flux dialyzers in solute clearance and biocompatibility profile. 32 patients were sequentially dialyzed with Leoceed-21HX, Polypure-22S+, Rexsys-27H and VIE-21A. Primary outcome was ?2-microglobulin removal. Secondary outcomes were (i) extraction of other uremic solutes (ii) parameters of inflammation and nutrition and (iii) comparative quantification of perdialytic albumin losses (using total 'TDC' vs partial 'PDC' collection of dialysate). Significant increases in removal rates of ?2-microglobulin (84.7?±?0.8 vs 71.6?±?0.8?mg/L), myoglobin (65.9?±?1.3 vs 38.6?±?1.3?µg/L), free immunoglobulin light chains Kappa (74.9?±?0.8 vs 55.6?±?0.8?mg/L), ?-trace protein (54.8?±?1.3 vs 26.8?±?1.4?mg/L) and orosomucoid (11.0?±?1.1 vs 6.0?±?1.1?g/L) but not myostatin (14.8?±?1.5 vs 13.0?±?1.5?ng/mL) were observed in HDF compared to HD when pooling all dialyzers. Rexsys and VIE-A use in both HD and HDF subgroups was associated to a better removal of middle/large-size molecules compared to Leoceed and Polypure, except ?2-microglobulin for Rexsys. Inflammatory parameters were unchanged between dialyzers without any interaction with dialysis modality. Mean dialysate albumin loss was comparable between TDC and PDC (1.855 vs 1.826?g/session for TDC and PDC respectively). In addition, a significant difference in albumin loss was observed between dialyzers with the highest value (4.5?g/session) observed using Rexsys. Use of all dialyzers was associated with good removals of the large spectrum of uremic toxins tested and good biocompatibility profiles, with an additional gain in removal performances with HDF. Larger surface area, thinner wall and resultant very high ultrafiltration coefficient of Rexsys should be taken into account in its clear performance advantages.


PROVIDER: S-EPMC6892817 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2010-01-01 | S-EPMC2989792 | BioStudies
2018-01-01 | S-EPMC6585607 | BioStudies
2017-01-01 | S-EPMC5837492 | BioStudies
2012-01-01 | S-EPMC3561063 | BioStudies
2014-01-01 | S-EPMC4080337 | BioStudies
2015-01-01 | S-EPMC4381674 | BioStudies
2020-01-01 | S-EPMC7259768 | BioStudies
2011-01-01 | S-EPMC3358998 | BioStudies
2019-01-01 | S-EPMC6887955 | BioStudies
2018-01-01 | S-EPMC5846770 | BioStudies